#United States #Montreal #FarmaMondo #ExCellThera #Zemcelpro®

ExCellThera's New Expansion in Asia

ExCellThera Inc., a leading innovator in blood stem cell therapies, has officially partnered with FarmaMondo SA to distribute its groundbreaking product, Zemcelpro® (dorocubicel), in three pivotal markets: Argentina, Hong Kong, and Singapore. This development is anticipated to significantly improve patient access to vital therapies for hematological malignancies.

What is Zemcelpro®?

Zemcelpro®, also known as UM171 Cell Therapy, is a cutting-edge cryopreserved hematopoietic stem cell transplantation product. It's specially designed to facilitate stem cell transplants for patients diagnosed with critical blood cancers. This product comprises two essential components: UM171-expanded CD34+ cells, known as dorocubicel, and unexpanded CD34- cells, both sourced from the same cord blood unit. In the European Union, it's primarily indicated for adults who require allogeneic hematopoietic stem cell transplantation but face challenges in finding suitable donor cells.

With conditional approval granted by the European Commission, the urgency to ensure availability in international markets has become paramount. Hence, ExCellThera has strategically allied with FarmaMondo, renowned for its expertise in enhancing access to innovative and complex therapies, especially within emerging markets.

The Agreement's Significance

Under the latest agreement, FarmaMondo will spearhead early access programs for Zemcelpro® across the discussed regions. This collaboration aims to leverage FarmaMondo’s substantial knowledge in regulatory compliance and specialized distribution channels, ultimately ensuring that patients can easily benefit from the innovative therapy.

David Millette, the CEO of Cordex, emphasized the importance of this agreement: “This collaboration signifies a critical step in our strategy to provide meaningful access to Zemcelpro® for patients grappling with pressing unmet medical needs. The response from the medical community highlights the urgent need for innovative therapies to manage blood cancers effectively.”

Future Aspirations and Developments

With Zemcelpro®, ExCellThera aims to break new ground in international markets beyond just these initial territories, continuously seeking new partnerships that can facilitate broader access. As noted by Yaron Spigel, CEO of FarmaMondo, the partnership aligns perfectly with their mission to provide essential, life-saving treatments in complex regulatory environments.

Cordex is steadfast in its commitment to advancing its global regulatory strategy, including plans for additional approvals from health authorities worldwide, such as those in the United States, Canada, the UK, and Switzerland. Following successful clinical evaluations involving over 120 patients with hematological malignancies across trials in various regions, there is momentum for future Phase 3 studies targeting subsets of patients with significant risks and limited options.

In addition to adult treatments, there are ongoing investigations into Zemcelpro®’s efficacy in treating pediatric populations and non-malignant hematological diseases. The journey for expanding this therapy into new demographics showcases the commitment to innovation and patient care in the realm of stem cell therapy.

Conclusion

The partnership between ExCellThera and FarmaMondo heralds an essential evolution in the distribution of innovative medical therapies in Asia. As they work together to navigate the complexities of market access, this collaboration has the potential to redefine treatment landscapes for patients facing serious blood disorders in underrepresented markets. By addressing regulatory challenges head-on, they aim to enhance the lives of countless patients and pave the way for broader acceptance of advanced cell therapies worldwide.